home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

58.51 -0.56 (-0.95%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

17 18 Next >

BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake ↗

November 07, 2023

The company's recently FDA-approved gene therapy is struggling to gain traction.

Via Investor's Business Daily

Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday ↗

November 07, 2023

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

November 04, 2023

A 19% decline in the Nasdaq Composite over the past two years represents an ideal time for opportunistic long-term investors to go shopping for bargains.

Via The Motley Fool

Topics Stocks

Earnings Outlook For Biomarin Pharmaceutical ↗

October 31, 2023

Via Benzinga

15 Analysts Have This to Say About Biomarin Pharmaceutical ↗

October 16, 2023

Via Benzinga

What 16 Analyst Ratings Have To Say About Biomarin Pharmaceutical ↗

September 13, 2023

Via Benzinga

Earnings Outlook For Biomarin Pharmaceutical ↗

July 28, 2023

Via Benzinga

Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today? ↗

October 27, 2023

In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a

Via Benzinga

3 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

October 19, 2023

These three lesser-known biotech companies are profitable and growing revenue.

Via The Motley Fool

Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty ↗

September 28, 2023

Raymond James initiated coverage on BioMarin Pharmaceuticals Inc (NASDAQ: BMRN) with a Market Perform rating, noting sparsity in

Via Benzinga

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

September 23, 2023

A nearly 15% decline in the growth-driven Nasdaq Composite from its record high is a blessing in disguise for opportunistic long-term investors.

Via The Motley Fool

Topics Stocks

What 9 Analyst Ratings Have To Say About Biomarin Pharmaceutical ↗

July 27, 2023

Via Benzinga

What 13 Analyst Ratings Have To Say About Biomarin Pharmaceutical ↗

July 03, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023 ↗

September 28, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

September 15, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023 ↗

September 18, 2023

Via Benzinga

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗

September 15, 2023

Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.

Via Investor's Business Daily

4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

September 02, 2023

The innovation-fueled Nasdaq Composite remains 13% below its all-time high, which means bargains can still be found.

Via The Motley Fool

Topics Stocks

4 Unforgettable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip ↗

August 12, 2023

With the growth-driven Nasdaq Composite still 14% below its record-closing high, deals abound.

Via The Motley Fool

Topics Stocks

Biomarin's Q2 Beat Street View, Raises Voxzogo Annual Guidance Driven By Global Demand ↗

August 01, 2023

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) reported a Q2 adjusted EPS of $0.54, higher than $0.41 a year ago and beating the

Via Benzinga

3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True ↗

July 06, 2023

These high return biotech stocks offer tremendous upside ahead and are likely to soar on the back of several growth drivers

Via InvestorPlace

Is BioMarin Ready To Rebound After FDA Approval Of Roctavian?

July 06, 2023

BioMarin gets FDA approval for Roctavian and earned an upgrade because of it; shares may be ready to rebound but there are still hurdles.

Via MarketBeat

Earnings Scheduled For July 31, 2023 ↗

July 31, 2023

Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 ↗

July 27, 2023

Via Benzinga

BioMarin Presents ~20% Upside Amid Voxzogo's Success and Slow Roctavian Uptake, Analyst Says ↗

July 05, 2023

BMO Capital Markets has upgraded BioMarin Pharmaceutical Inc (NASDAQ: BMRN) to Outperform from Market Perform, and the price target remains at $102,

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023 ↗

July 05, 2023

Via Benzinga

BioMarin's Roctavian US Launch: Focus on Commercial Strategy Amid EU Failures, Analyst Points Out ↗

June 30, 2023

On Thursday, The FDA approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults

Via Benzinga

Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories ↗

June 30, 2023

New York Post

Via Benzinga

BioMarin's Delayed Roctavian Scores FDA Nod As First Hemophilia A Gene Therapy In US ↗

June 30, 2023

The FDA approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Roctavian (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A (congenital factor VIII (FVIII) deficiency...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com